Lectures

2014

  • Evi Kostenis: Deciphering signaling and function of orphan G protein-coupled receptors with label-free biosensors. Invited lecture at the Frontiers in Medicinal Chemistry 2014 Conference in Tübingen.

  • Evi Kostenis: Targeting GPR17 to promote remyelination in the CNS: should we switch it on or off? Invited lecture at a symposium of the German society for Pharmacology & Toxicology in Hannover 2014.

  • Ute Haußmann: Application of the NanoPro 1000 platform for analysis of amino-terminal amyloid-beta peptide variants. Presentation at European Protein Simple User Meeting, 12-13 May 2014, Paris, France.

  • Christa E. Müller: Development of dual- and multi-target drugs for the treatment of neurodegenerative diseases. Lecture at the Frontiers in Medicinal Chemistry 2014 Conference in Tübingen.

2013

  • Anja Schneider:  Das Neuroallianz Konsortium aus Sicht der akademischen Partner: Biomarkerentwicklung bei neurodegenerativen Erkrankungen. Vortrag Health 3.0, Düsseldorf, Dezember 2013.

  • Christa E. Müller: Neue Wege in der Arzneistoff-Entwicklung durch Kooperation zwischen Wissenschaft und Wirtschaft: das Beispiel Neuroallianz. Vortrag Health 3.0, Düsseldorf, December 2013.

  • Meryem Köse, Kirsten Ritter, Katharina Sylvester, Michel Gillard, Evi Kostenis, and Christa E. Müller: Synthesis and evaluation of [3H]PSB-12150 – a useful tool for studying the orphan G protein-coupled receptor GPR17. Poster presentation at DPhG-Jahrestagung.

  • Evi Kostenis, Christa Müller: GPR17-Agonisten und Screening-Assay – Grundlage für die Entwicklung zur Behandlung von MS. ZukunftErfindenNRW, 14 January 2013.

2012

  • Anita John, University Bonn: MicroRNAs and neurodegenerative disorders; BioPharma Neuroprotection Workshop, Hamburg, 2 February 2012.

  • Barbara Stegmann, UCB: Neuroallianz Consortium – A Life Example for an Academic-Industry Cooperation; BioPharma Neuroprotection Workshop, Hamburg, 2 February 2012.

  • Jens Wiltfang, University Duisburg-Essen: Translational dementia biomarker research: From predictive molecular diagnosis to novel preventive therapies; BioPharma Neuroprotection Workshop, Hamburg, 2 February 2012.

2011

  • Reiner Dieden, Director Analytical & Physical Chemistry & Log, UCB Pharma s. A., Belgium: Establishing a Compound Management Facility at the University of Bonn within the Neuroallianz Consortium; IQPC Compound Management, London, May 17th, 2011.
     
  • Martin Hofmann-Apitius, Fraunhofer-Institut SCAI: IT for Better Healthcare: Fundamental Challenges and a Reality Check based on Experiences from Selected Projects; I-HEALTH, Brüssel, 3./4. Okt. 2011.
     
  • Martin Hofmann-Apitius, Fraunhofer-Institut SCAI: The Neuroallianz IT platform: Enabling knowledge discovery in an IT environment supporting collaborative research between academic and pharmaceutical partners; 9th Pharmaceutical IT Conference, London, 15./16. Sept. 2011.
     
  • Christa Müller: Vortrag zur Vorstellung der Neuroallianz im Rotary Club Bornheim, 2011.

2010

  • Dr. Anna Lisa Picciolo-Lehrke, R&D Partnering Business Development, UCB Pharma GmbH, Monheim: Neuroallianz Consortium – A Life Example for Academic and Industry Partnership. b-it Wirtschaftsforum 2010

  • Prof. Dr. Christa E. Müller, Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität, Bonn; Gründungssprecherin des BMBF-geförderten Konsortiums Neuroallianz, Bonn: Neue Wege der Arzneistoff-Entwicklung durch Kooperationen zwischen Wissenschaft und Wirtschaft: das Beispiel Neuroallianz. Bioriver 2010

  • Prof. Dr. Martin Hofmann-Apitius, Fraunhofer-Institut SCAI: Combining Text Mining and Virtual Screening: Direct Use of Information Extracted from the Scientific Literature for In Silico Experimentation. Pharmaceutical Sciences World Congress (PSWC), 17 November 2010 & Jackson Lab (Bar Habor, Maine) 19 November 2010 & University of Michigan in Ann Arbour (Michigan), 22 November 2010

  • Christa Müller: Vortrag zur Vorstellung der Neuroallianz im Rotary Club Bonn Museumsmeile, 2010.

Facts

To provide the German location of biotechnology and pharma industry with fresh impulsion, the German Federal Ministry for Education and Research (BMBF) started the pharma initiative "BioPharma: The Strategy Competition for Future Medicines". The Neuroallianz Consortium was nominated for this initiative.

The Neuroallianz Consortium has created a novel strategic partnership where various academic institutions and companies are working jointly on innovative diagnostic and therapeutic research projects. The aim is to efficiently transform research into benefits for the patients.

Main focuses are diagnostic and therapy of neurodegenerative diseases such as Parkinson's Disease, or Alzheimer's Dementia, and Epilepsy.

Duration: 2009 – 2018

Budget: 40 Mio. €

Logo BMBF